Literature DB >> 11258980

Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes.

S Lin1, L M Del Razo, M Styblo, C Wang, W R Cullen, D J Thomas.   

Abstract

Thioredoxin reductase (TR), an NADPH-dependent flavoenzyme that catalyzes the reduction of many disulfide-containing substrates, plays an important role in the cellular response to oxidative stress. Trivalent arsenicals, especially methyl As that contains trivalent arsenic (MAs(III)), are potent noncompetitive inhibitors of TR purified from mouse liver. Because MAs(III) is produced in the biomethylation of As, it was postulated that the extent of inhibition of TR in cultured rat hepatocytes would correlate with the intracellular concentration of methyl As. Exposure of cultured hepatocytes to inorganic As(III) (iAs(III)), MAs(III), or aurothioglucose (ATG, a competitive inhibitor of TR activity) for 30 min caused a concentration-dependent reduction in TR activity. The estimated IC(50) was >>100 microM for iAs(III), approximately 10 microM for ATG, and approximately 3 microM for MAs(III). In hepatocytes exposed to 1 microM MAs(III) for up to 24 h, the inhibition of TR activity was maximal ( approximately 40%) after exposure for 15 min. After exposure for 3 h [when most MAs(III) has been converted to dimethyl As (DMAs)], TR activity in these cells had returned to control levels. Notably, exposure of the cell to 50 microM DMAs(III) did not affect TR activity. In hepatocytes exposed to 10 microM iAs(III) for up to 24 h, the inhibition of TR activity was progressive; at 24 h, activity was reduced approximately 35%. Following exposure to iAs(III) or MAs(III), the extent of inhibition of TR activity correlated strongly with the intracellular concentration of MAs. Taken together, these results suggest that arsenicals formed in the course of cellular metabolism of As are potent inhibitors of TR activity. In particular, MAs(III), an intermediate in the metabolic pathway, is an especially potent inhibitor of TR. Hence, the capacity of cells to produce or consume the intermediates in the pathway for As methylation may be an important determinant of susceptibility to the toxic effects of As.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11258980     DOI: 10.1021/tx0001878

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  35 in total

1.  Arsenic exposure and toxicology: a historical perspective.

Authors:  Michael F Hughes; Barbara D Beck; Yu Chen; Ari S Lewis; David J Thomas
Journal:  Toxicol Sci       Date:  2011-07-12       Impact factor: 4.849

2.  Direct analysis and stability of methylated trivalent arsenic metabolites in cells and tissues.

Authors:  Jenna M Currier; Milan Svoboda; Tomáš Matoušek; Jiří Dědina; Miroslav Stýblo
Journal:  Metallomics       Date:  2011-10-21       Impact factor: 4.526

3.  Oxidation state specific analysis of arsenic species in tissues of wild-type and arsenic (+3 oxidation state) methyltransferase-knockout mice.

Authors:  Jenna M Currier; Christelle Douillet; Zuzana Drobná; Miroslav Stýblo
Journal:  J Environ Sci (China)       Date:  2016-07-18       Impact factor: 5.565

4.  Arsenic exposure, diabetes-related genes and diabetes prevalence in a general population from Spain.

Authors:  Maria Grau-Perez; Ana Navas-Acien; Inmaculada Galan-Chilet; Laisa S Briongos-Figuero; David Morchon-Simon; Jose D Bermudez; Ciprian M Crainiceanu; Griselda de Marco; Pilar Rentero-Garrido; Tamara Garcia-Barrera; Jose L Gomez-Ariza; Jose A Casasnovas; Juan C Martin-Escudero; Josep Redon; F Javier Chaves; Maria Tellez-Plaza
Journal:  Environ Pollut       Date:  2018-02-21       Impact factor: 8.071

5.  Metabolism and toxicity of arsenic in human urothelial cells expressing rat arsenic (+3 oxidation state)-methyltransferase.

Authors:  Zuzana Drobná; Stephen B Waters; Vicenta Devesa; Anne W Harmon; David J Thomas; Miroslav Stýblo
Journal:  Toxicol Appl Pharmacol       Date:  2005-09-01       Impact factor: 4.219

6.  Organoarsenicals inhibit bacterial peptidoglycan biosynthesis by targeting the essential enzyme MurA.

Authors:  Luis D Garbinski; Barry P Rosen; Masafumi Yoshinaga
Journal:  Chemosphere       Date:  2020-04-27       Impact factor: 7.086

7.  A semi-mechanistic integrated toxicokinetic-toxicodynamic (TK/TD) model for arsenic(III) in hepatocytes.

Authors:  Spyros K Stamatelos; Ioannis P Androulakis; Ah-Ng Tony Kong; Panos G Georgopoulos
Journal:  J Theor Biol       Date:  2012-10-12       Impact factor: 2.691

Review 8.  Oxidative mechanism of arsenic toxicity and carcinogenesis.

Authors:  Honglian Shi; Xianglin Shi; Ke Jian Liu
Journal:  Mol Cell Biochem       Date:  2004-01       Impact factor: 3.396

9.  Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia.

Authors:  S Talbot; R Nelson; W T Self
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

10.  Exposure to monomethylarsonous acid (MMA(III)) leads to altered selenoprotein synthesis in a primary human lung cell model.

Authors:  Sarah R Meno; Rebecca Nelson; Korry J Hintze; William T Self
Journal:  Toxicol Appl Pharmacol       Date:  2008-11-27       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.